FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097156911> ?p ?o ?g. }

• W2097156911 endingPage "e1920" @default.
• W2097156911 startingPage "e1920" @default.
• W2097156911 abstract "Background Trypanosoma brucei (T.b.) gambiense Human African trypanosomiasis (HAT; sleeping sickness) is a fatal disease. Until 2009, available treatments for 2nd stage HAT were complicated to use, expensive (eflornithine monotherapy), or toxic, and insufficiently effective in certain areas (melarsoprol). Recently, nifurtimox-eflornithine combination therapy (NECT) demonstrated good safety and efficacy in a randomised controlled trial (RCT) and was added to the World Health Organisation (WHO) essential medicines list (EML). Documentation of its safety profile in field conditions will support its wider use. Methodology In a multicentre, open label, single arm, phase IIIb study of the use of NECT for 2nd stage T.b. gambiense HAT, all patients admitted to the trial centres who fulfilled inclusion criteria were treated with NECT. The primary outcome was the proportion of patients discharged alive from hospital. Safety was further assessed based on treatment emergent adverse events (AEs) occurring during hospitalisation. Principal Findings 629 patients were treated in six HAT treatment facilities in the Democratic Republic of the Congo (DRC), including 100 children under 12, 14 pregnant and 33 breastfeeding women. The proportion of patients discharged alive after treatment completion was 98.4% (619/629; 95%CI [97.1%; 99.1%]). Of the 10 patients who died during hospitalisation, 8 presented in a bad or very bad health condition at baseline; one death was assessed as unlikely related to treatment. No major or unexpected safety concerns arose in any patient group. Most common AEs were gastro-intestinal (61%), general (46%), nervous system (mostly central; 34%) and metabolic disorders (26%). The overall safety profile was similar to previously published findings. Conclusions/Significance In field conditions and in a wider population, including children, NECT displayed a similar tolerability profile to that described in more stringent clinical trial conditions. The in-hospital safety was comparable to published results, and long term efficacy will be confirmed after 24 months follow-up. Registration The trial is registered at ClinicalTrials.gov, number NCT00906880." @default.
• W2097156911 created "2016-06-24" @default.
• W2097156911 creator A5008879221 @default.
• W2097156911 creator A5009629316 @default.
• W2097156911 creator A5011717442 @default.
• W2097156911 creator A5013205553 @default.
• W2097156911 creator A5018629090 @default.
• W2097156911 creator A5023161017 @default.
• W2097156911 creator A5023585185 @default.
• W2097156911 creator A5054460096 @default.
• W2097156911 creator A5056055869 @default.
• W2097156911 creator A5056513154 @default.
• W2097156911 creator A5056863187 @default.
• W2097156911 creator A5063139152 @default.
• W2097156911 creator A5071348863 @default.
• W2097156911 creator A5076945656 @default.
• W2097156911 creator A5090892765 @default.
• W2097156911 date "2012-11-29" @default.
• W2097156911 modified "2023-10-16" @default.
• W2097156911 title "In-Hospital Safety in Field Conditions of Nifurtimox Eflornithine Combination Therapy (NECT) for T. b. gambiense Sleeping Sickness" @default.
• W2097156911 cites W1995305610 @default.
• W2097156911 cites W1998746678 @default.
• W2097156911 cites W1999562946 @default.
• W2097156911 cites W2002241467 @default.
• W2097156911 cites W2036763008 @default.
• W2097156911 cites W2037395635 @default.
• W2097156911 cites W2049691096 @default.
• W2097156911 cites W2082541677 @default.
• W2097156911 cites W2100794308 @default.
• W2097156911 cites W2104765579 @default.
• W2097156911 cites W2127063113 @default.
• W2097156911 cites W2132921308 @default.
• W2097156911 cites W2142014232 @default.
• W2097156911 cites W2150290224 @default.
• W2097156911 cites W2151799620 @default.
• W2097156911 cites W2159158593 @default.
• W2097156911 cites W2165320275 @default.
• W2097156911 doi "https://doi.org/10.1371/journal.pntd.0001920" @default.
• W2097156911 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3510081" @default.
• W2097156911 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23209861" @default.
• W2097156911 hasPublicationYear "2012" @default.
• W2097156911 type Work @default.
• W2097156911 sameAs 2097156911 @default.
• W2097156911 citedByCount "39" @default.
• W2097156911 countsByYear W20971569112013 @default.
• W2097156911 countsByYear W20971569112014 @default.
• W2097156911 countsByYear W20971569112015 @default.
• W2097156911 countsByYear W20971569112016 @default.
• W2097156911 countsByYear W20971569112017 @default.
• W2097156911 countsByYear W20971569112018 @default.
• W2097156911 countsByYear W20971569112019 @default.
• W2097156911 countsByYear W20971569112020 @default.
• W2097156911 countsByYear W20971569112021 @default.
• W2097156911 countsByYear W20971569112022 @default.
• W2097156911 countsByYear W20971569112023 @default.
• W2097156911 crossrefType "journal-article" @default.
• W2097156911 hasAuthorship W2097156911A5008879221 @default.
• W2097156911 hasAuthorship W2097156911A5009629316 @default.
• W2097156911 hasAuthorship W2097156911A5011717442 @default.
• W2097156911 hasAuthorship W2097156911A5013205553 @default.
• W2097156911 hasAuthorship W2097156911A5018629090 @default.
• W2097156911 hasAuthorship W2097156911A5023161017 @default.
• W2097156911 hasAuthorship W2097156911A5023585185 @default.
• W2097156911 hasAuthorship W2097156911A5054460096 @default.
• W2097156911 hasAuthorship W2097156911A5056055869 @default.
• W2097156911 hasAuthorship W2097156911A5056513154 @default.
• W2097156911 hasAuthorship W2097156911A5056863187 @default.
• W2097156911 hasAuthorship W2097156911A5063139152 @default.
• W2097156911 hasAuthorship W2097156911A5071348863 @default.
• W2097156911 hasAuthorship W2097156911A5076945656 @default.
• W2097156911 hasAuthorship W2097156911A5090892765 @default.
• W2097156911 hasBestOaLocation W20971569111 @default.
• W2097156911 hasConcept C126322002 @default.
• W2097156911 hasConcept C136764020 @default.
• W2097156911 hasConcept C181199279 @default.
• W2097156911 hasConcept C185592680 @default.
• W2097156911 hasConcept C187212893 @default.
• W2097156911 hasConcept C197934379 @default.
• W2097156911 hasConcept C203014093 @default.
• W2097156911 hasConcept C2777497464 @default.
• W2097156911 hasConcept C2777625466 @default.
• W2097156911 hasConcept C2778143080 @default.
• W2097156911 hasConcept C2778792689 @default.
• W2097156911 hasConcept C2780722877 @default.
• W2097156911 hasConcept C2781049234 @default.
• W2097156911 hasConcept C41008148 @default.
• W2097156911 hasConcept C535046627 @default.
• W2097156911 hasConcept C55493867 @default.
• W2097156911 hasConcept C71924100 @default.
• W2097156911 hasConcept C71928629 @default.
• W2097156911 hasConceptScore W2097156911C126322002 @default.
• W2097156911 hasConceptScore W2097156911C136764020 @default.
• W2097156911 hasConceptScore W2097156911C181199279 @default.
• W2097156911 hasConceptScore W2097156911C185592680 @default.
• W2097156911 hasConceptScore W2097156911C187212893 @default.
• W2097156911 hasConceptScore W2097156911C197934379 @default.
• W2097156911 hasConceptScore W2097156911C203014093 @default.
• W2097156911 hasConceptScore W2097156911C2777497464 @default.

• next